Archit Organosys to buy 92.2% of Archit Life Science in all-share deal
What's the deal? Archit OrganosysDealroom has a profile for this one. Try Dealroom →, a commodity chemicals company based in Ahmedabad, India, will acquire 92.2% of Archit Life ScienceDealroom has a profile for this one. Try Dealroom → through a share swap. Its board approved the plan on September 3, 2026, subject to shareholder and regulatory approval.
How is it structured? Rather than paying cash, Archit Organosys will issue up to 37,248,344 new equity shares at Rs. 65 each — a Rs. 10 face value plus a Rs. 55 premium. In exchange, it receives 18,624,172 shares of Archit Life Science, valued at Rs. 130 each.
Who gets the shares? The preferential allotment goes to 44 proposed allottees across promoter and non-promoter categories. Promoters Archana Kandarp Amin and Kandarp Krishnakant Amin each end up with the largest stakes, at 17.47% and 17.11% respectively.
Why now? To make room for the deal, the board also approved raising authorised share capital from Rs. 25 crore to Rs. 60 crore, lifting the shares it can issue from 25,000,000 to 60,000,000. Registered valuer M/s. Procurve Valux Private LimitedDealroom has a profile for this one. Try Dealroom → supplied the valuation report, and the relevant date for pricing was fixed at August 31, 2026.
What's the endgame? The move folds Archit Life Science almost entirely into Archit Organosys, consolidating two related businesses under one listed entity and a shared promoter group.
What could go wrong? The entire issue and acquisition still need approval at the coming annual general meeting, plus statutory and regulatory sign-off. Because the deal is cash-free and heavily weighted toward insiders, minority shareholders will be watching the valuation closely.
The signal: Share swaps let asset-rich but cash-conscious companies consolidate without draining reserves. Here, it also tightens promoter control — a common pattern in India's small-cap chemicals sector, where family-linked firms increasingly merge to streamline listed structures.
Read more: equitybulls.com
Image credit: myfuture.com
